TY - JOUR T1 - Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia JF - medRxiv DO - 10.1101/2020.06.17.20134031 SP - 2020.06.17.20134031 AU - Francesco Salton AU - Paola Confalonieri AU - Pierachille Santus AU - Sergio Harari AU - Raffaele Scala AU - Simone Lanini AU - Valentina Vertui AU - Tiberio Oggionni AU - Antonella Caminati AU - Vincenzo Patruno AU - Mario Tamburrini AU - Alessandro Scartabellati AU - Mara Parati AU - Massimiliano Villani AU - Dejan Radovanovic AU - Sara Tomassetti AU - Claudia Ravaglia AU - Venerino Poletti AU - Andrea Vianello AU - Anna Talia Gaccione AU - Luca Guidelli AU - Rita Raccanelli AU - Paolo Lucernoni AU - Donato Lacedonia AU - Maria Pia Foschino Barbaro AU - Stefano Centanni AU - Michele Mondoni AU - Matteo Davì AU - Alberto Fantin AU - Xueyuan Cao AU - Lucio Torelli AU - Antonella Zucchetto AU - Marcella Montico AU - Annalisa Casarin AU - Micaela Romagnoli AU - Stefano Gasparini AU - Martina Bonifazi AU - Pierlanfranco D’Agaro AU - Alessandro Marcello AU - Danilo Licastro AU - Barbara Ruaro AU - Maria Concetta Volpe AU - Reba Umberger AU - Umberto Meduri AU - Marco Confalonieri Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/20/2020.06.17.20134031.abstract N2 - Background In hospitalized patients with COVID-19 pneumonia, progression to acute respiratory failure requiring invasive mechanical ventilation (MV) is associated with significant morbidity and mortality. Severe dysregulated systemic inflammation is the putative mechanism.Research Question Will early prolonged methylprednisolone (MP) treatment accelerate disease resolution, decreasing the need for ICU and mortality?Study Design and Methods We conducted a multicenter, observational study to explore the association between exposure to prolonged, low-dose, MP treatment and need for ICU referral, intubation or death within 28 days (composite primary endpoint) in patients with severe COVID-19 pneumonia admitted to Italian respiratory high-dependency units. Secondary outcomes were invasive MV-free days and changes in C-reactive protein (CRP) levels.Results Findings are reported as MP (n=83) vs. control (n=90). The composite primary endpoint was met by 19 vs. 40 [adjusted hazard ratio (HR) 0.41; 95% confidence interval (CI): 0.24-0.72]. Transfer to ICU and need for invasive MV was necessary in 15 vs. 27 (p=0.07) and 14 vs. 26 (p=0.10), respectively. By day 28, the MP group had fewer deaths (6 vs. 21, adjusted HR=0.29; 95% CI: 0.12-0.73) and more days off invasive MV (24.0 ± 9.0 vs. 17.5 ± 12.8; p=0.001). Study treatment was associated with rapid improvement in PaO2:FiO2 and CRP levels. The complication rate was similar for the two groups (p=0.84).Interpretation In patients with severe COVID-19 pneumonia, early administration of prolonged MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence. Randomized controlled studies are needed to confirm these findings.Clinical trial registration ClinicalTrials.gov. Identifier: NCT04323592.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04323592Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04323592?term=confalonieri&draw=2&rank=1 Funding StatementThis material is the result of work supported with the resources and use of facilities at the University Hospital of Trieste and Memphis VA Medical Center. The contents of this commentary do not represent the views of the US Department of Veterans Affairs nor of the United States or Italian Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the referral Ethics Committee for the Coordinating Centre (University Hospital of Trieste, #CEUR-2020-Os-052).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available on reasonable external request.ARDSacute respiratory distress syndromeARFacute respiratory failureCRPC-reactive proteinICUintensive care unitIVintravenousMPmethylprednisoloneMVmechanical ventilationNPPVnoninvasive positive pressure ventilationRHDUrespiratory high dependency unit ER -